Clinical trials: Residual
Non-Small Cell Lung Cancer (NSCLC)
MRD and Imaging Guided Adaptive Neoadjuvant Therapy for Resectable NSCLC
Neoadjuvant immunotherapy combined with platinum-based doublet chemotherapy has been established as the standard of care for driver-gene-negative (EGFR/ALK wild-type) stage II-IIIB non-small cell lung cancer (NSCLC), yielding…
- Trial name
- NCT07885709
- Testing
- PD-1 inhibitor, Carboplatin, Nab-paclitaxel
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking University People's Hospital
Acute Myeloid Leukemia
Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid Leukemia
Ceplene/IL-2 remission maintenance therapy has been shown to significantly prolong Leukemia Free Survival in patients with Acute Myeloid Leukemia (AML) in first complete remission.
- Trial name
- NCT01347996
- Testing
- histamine dihydrochloride and IL-2
- Where
- Sweden
- Volunteers
- 84 people
- Sponsor
- Cytovia, Inc.
COPD, Lung Diseases
Effect of Indacaterol Maleate in Chronic Obstructive Pulmonary Disease (COPD) on Lung Volume and Related Dyspnea
The purpose of this study is to determine whether indacaterol maleate 300 micrograms (mcg) is effective in the acute treatment of COPD and in particular on reducing lung hyperinflation and dynamic volumes.
- Conditions
- COPD, Lung Diseases, Dyspnea, Hypoxemia
- Trial name
- NCT01377051
- Testing
- Indacaterol maleate
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- University of Milan
Tube Feeding
Effect of Methylnaltrexone (Relistor) on Digestion and Tolerance to Tube Feeding in Patients Treated With Opiates
It is hypothesized that using methylnaltrexone in addition to pain killer narcotics (opiates) in patients will result in increased tube feeding rates with more frequent nutrition at goal calorie rate.
- Trial name
- NCT01360372
- Testing
- Methylnaltrexone, Saline injection
- Where
- 2 sites in United States
- Sponsor
- Drexel University
Type I Hypersensitivity
Assessment of Residual Allergenicity of Tree (Birch, Hazel, and Alder) Pollen Allergoid Using Skin Prick Testing
The purpose of this study is to evaluate the residual allergenicity of Tree MATA (modified pollen allergen tyrosine adsorbate) by skin prick testing.
- Trial name
- NCT00107705
- Testing
- Tree MATA MPL
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- Allergy Therapeutics
Prolonged Air Leak, Phrenic Nerve
Postoperative Effects of Intraoperative Temporary Phrenic Nerve Paralysis in Lung Resection Surgery
This prospective clinical study aimed to evaluate the postoperative effects of temporary phrenic nerve paralysis induced by intraoperative phrenic nerve crush during lung resection surgery.
- Conditions
- Prolonged Air Leak, Phrenic Nerve, EMG
- Trial name
- PNCrush (NCT07259031)
- Testing
- İntraoperative phrenic nerve compression
- Where
- Turkey (Türkiye)
- Volunteers
- 55 people
- Sponsor
- Ferdane Melike Duran
Non-Small Cell Lung Cancer
MRD-Guided Aumolertinib-Based Adjuvant Therapy for Resected EGFR-Mutant NSCLC
Despite complete (R0) resection, patients with EGFR-mutant stage IIA-IIIB non-small cell lung cancer (NSCLC) still face a substantial risk of postoperative recurrence.
- Trial name
- NCT07873086
- Testing
- Aumolertinib, Pemetrexed, Carboplatin
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking University People's Hospital
Hematologic Malignancies
Phase I Study to Assess the Tolerability and Efficacy of Nivolumab in Patients With Hematologic Malignancies
This is an open-label, dose escalation Phase I study to evaluate the tolerability and efficacy of single agent of Nivolumab as maintenance treatment to prevent relapse in patients with hematologic malignancies after allogeneic…
- Trial name
- NCT02985554
- Testing
- Nivolumab
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Chicago
Multiple Myeloma
Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma
This is a Phase 2 study, open-label, 2-cohort, multicenter, national, interventional in patients with newly diagnosed multiple myeloma.
- Trial name
- IFm2022-01 (NCT06353022)
- Testing
- Teclistamab, Talquetamab, Lenalidomide
- Where
- 19 sites in France
- Volunteers
- 103 people
- Sponsor
- Nantes University Hospital
Colorectal Cancer (MSI-H), Molecular Residual Disease
Research on Colorectal Cancer Recurrence Monitoring and Individualized Treatment Based on MRD
This study aims to evaluate whether plasma molecular residual disease (MRD), assessed using circulating tumor DNA (ctDNA), can help optimize the duration of immunotherapy in patients with metastatic microsatellite…
- Trial name
- NCT07775950
- Testing
- Discontinue NA Treatment, Continued Immunotherapy, Observation
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
Muscle Relaxants
The Association Between Residual Neuromuscular Block Risk Prediction Score and the Train-of-Four Ratio
evaluate the degree of association, and the predictive accuracy of the REPS (as a predictive tool) compared with the TOFr as a quantitative assessment tool for (rNMB) in surgical patients in the early postoperative phase.
- Trial name
- NCT06899048
- Testing
- residual neuromuscular block risk prediction score
- Where
- Egypt
- Volunteers
- 91 people
- Sponsor
- Assiut University
TNBC - Triple-Negative Breast Cancer, Minimal Residual Disease
CtDNA Based MRD Testing for NAC Monitoring in TNBC
A prospective, multicenter, observational study to evaluate the correlation of Molecular Residual Disease (MRD) detection using circulating tumor DNA guided test to pathological complete response (pCR) after neoadjuvant…
- Trial name
- B-STRONGER-I (NCT06230185)
- Where
- 14 sites in United States
- Volunteers
- 422 people
- Sponsor
- Personalis Inc.
Multiple Myeloma
Pembrolizumab (MK-3475) in MM Patients With Residual Disease
This is a national, multicenter, open label single-arm, non-comparative study that will determine the efficacy, safety and the changes in selected pharmacodynamics markers of MK-3475 monotherapy administered as consolidation…
- Trial name
- NCT02636010
- Testing
- Pembrolizumab
- Where
- 11 sites in Spain
- Volunteers
- 20 people
- Sponsor
- PETHEMA Foundation
Brain and Central Nervous System Tumors
High-Dose Methotrexate in Treating Young Patients With Residual Ependymoma
RATIONALE: Drugs used in chemotherapy, such as methotrexate, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00287924
- Testing
- methotrexate, adjuvant therapy
- Where
- 21 sites in Ireland, United Kingdom
- Volunteers
- 29 people
- Sponsor
- Children's Cancer and Leukaemia Group
Leukemia
Vaccine Therapy in Treating Patients With Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill cancer cells. Colony-stimulating factors, such as GM-CSF, may increase the number of immune cells found in bone marrow or…
- Trial name
- CML0206 (NCT00466726)
- Testing
- bcr-abl p210-b3a2 breakpoint-derived multipeptide vaccine, sargramostim
- Where
- 17 sites in Italy
- Volunteers
- 57 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Neuromuscular Residual Curarization
Comparison of the TOFScan and the WiTOF During Recovery of Neuromuscular Function
The purpose of this study is to compare two neuromuscular blockade monitors on recovery from an ATRACURIUM intra veinous injection for surgery. The TOFscan, a wired connected monitors and the WiTOF, a wireless connected monitor.
- Trial name
- NCT05231525
- Testing
- WiTOF, TOFscan
- Where
- France
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Poitiers University Hospital
Nasopharyngeal Cancinoma (NPC)
Tislelizumab Combined With Capecitabine for Nasopharyngeal Carcinoma With Residual EBV DNA After Radiotherapy
This study aims to explore the efficacy and safety of tislelizumab combined with capecitabine in nasopharyngeal carcinoma patients with residual plasma EBV DNA after radiotherapy.
- Trial name
- NCT07067268
- Testing
- Adjuvant therapy
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Fudan University
Peripheral Arterial Disease, Stenosis
A Trail of Sperstent® Used for Residual Lesions of Femoropopliteal Arteries
This is a prospective, multi-center, randomized trial designed to investigate the efficacy and safety of Sperstent® peripheral spot stent system versus Everflex® self-expanding peripheral stent system in the endovascular…
- Conditions
- Peripheral Arterial Disease, Stenosis, Dissection
- Trial name
- SURF (NCT06539689)
- Testing
- Sperstent® peripheral spot stent system, Everflex® self-expanding peripheral stent system
- Where
- 12 sites in China
- Volunteers
- 240 people
- Sponsor
- FrontAce Scientific Co., Ltd
Urinary Retention
First-in-man Safety and Efficacy Trial of a Novel Non-invasive Bladder Emptying Device: The NIBED Study
The non-invasive bladder emptying device (NIBED) is a handheld medical device that is applied to the penis during urinating to aid bladder emptying in urinary retention patients with increased residual urine volume.
- Trial name
- NIBED pilot (NCT04919798)
- Testing
- Non-invasive bladder emptying device
- Where
- Switzerland
- Volunteers
- 10 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Non-seminomatous Germ Cell Tumors, Metastasis
Contribution of the Imaging to the Expression of intégrines αvβ3 for the Characterization of Residual Masses of Non-seminoma Tumors at the End of Chemotherapy
The purpose of this study is to evaluate the contribution of the imaging to the expression of intégrines αvβ3 for the characterization of the residual masses of non-seminoma tumors at the end of chemotherapy.
- Trial name
- TERMATEP (NCT02317393)
- Testing
- K5-RGD PET, FDG
- Where
- 5 sites in France
- Volunteers
- 16 people
- Sponsor
- Centre Francois Baclesse
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.